secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001104659-26-003038
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone closes $75M royalty sale to RTW for etripamil US net sales
--------------------------------------------------------------------

- Closed sale of royalty interest under Royalty Purchase Agreement with RTW Royalty I DAC.
- Received $75 million purchase price from funds managed by RTW.
- Royalty interest is on annual net product sales of etripamil in the United States.
- Previously disclosed on March 27, 2023; FDA approval of etripamil a condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926003038/0001104659-26-003038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926003038/tm262948d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-003038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer